Fleming Antibiotic Quotes

I doubt that Fleming could have obtained a grant for the discovery of penicillin on that basis [a requirement for highly detailed research plans] because he could not have said, 'I propose to have an accident in a culture so that it will be spoiled by a mould falling on it, and I propose to recognize the possibility of extracting an antibiotic from this mould.

It has been demonstrated that a species of penicillium produces in culture a very powerful antibacterial substance which affects different bacteria in different degrees. Generally speaking it may be said that the least sensitive bacteria are the Gram-negative bacilli, and the most susceptible are the pyogenic cocci ... In addition to its possible use in the treatment of bacterial infections penicillin is certainly useful... for its power of inhibiting unwanted microbes in bacterial cultures so that penicillin insensitive bacteria can readily be isolated.

Indeed, antibiotic resistance, a fear predicted by Alexander Fleming when accepting his Nobel Prize for penicillin, is a huge concern for many infectious bacterial diseases in the twenty-first century and has been described as a ‘ticking time bomb’ and the greatest ‘global threat’ of our time.

Alexander Fleming, the discoverer of penicillin. Dr. Fleming noted as early as 1929 in the British Journal of Experimental Pathology that numerous bacteria were already resistant to the drug he had discovered, and in a 1945 New York Times interview, he warned that improper use of penicillin would inevitably lead to the development of resistant bacteria. Fleming’s observations were prescient. At the time of his interview just 14 percent of Staphylococcus aureus bacteria were resistant to penicillin; by 1953, as the use of penicillin became widespread, 64 percent to 80 percent of the bacteria had become resistant and resistance to tetracycline and erythromycin was also being reported. (In 1995 an incredible 95 percent of staph was resistant to penicillin.) By 1960 resistant staph had become the most common source of hospital-acquired infections worldwide.

The development of antibiotics is one of the most successful stories in the history of medicine, but it is unclear whether its ending will be a completely happy one. Fleming prophetically warned in his 1945 Nobel lecture that the improper use of penicillin would lead to its becoming ineffective. The danger was not in taking too much; it was in taking too little to kill the bacteria but “enough to educate them to resist penicillin.

Clinicians have only one obligation: to do whatever they can to help their patients get better. Because of this, clinical practice has always been a hotbed for experimentation. Some experiments fail, some succeed, and some, like EMDR, dialectical behavior therapy, and internal family systems therapy, go on to change the way therapy is practiced. Validating all these treatments takes decades and is hampered by the fact that research support generally goes to methods that have already been proven to work. I am much comforted by considering the history of penicillin: Almost four decades passed between the discovery of its antibiotic properties by Alexander Fleming in 1928 and the final elucidation of its mechanisms in 1965.

penicillin, which was discovered in 1928 by Alexander Fleming and put to therapeutic medical uses from 1941. Penicillin had no relevance to TB specifically, but it opened the way to the development of a series of additional “magic bullets” and to the belief that TB could be eradicated globally by a spectacular technological fix. The first of these “wonder drugs” applicable to tuberculosis was the antibiotic streptomycin, which was discovered at Rutgers University by Selman Waksman in 1943.

Echoing Fleming’s warning, theorists of emerging diseases argue that antibiotics are a “nonrenewable resource” whose duration of efficacy is biologically limited. By the late twentieth century, this prediction was reaching fulfillment. At the same time as the discovery of new classes of antimicrobials had slowed to a trickle, the pharmaceutical marketplace staunched the flow by inhibiting research on medications that are likely to yield low profit margins.

commented on the future of antibiotic drugs. Perhaps, Fleming mused, a time would come when anyone with real or perceived illness could get penicillin. “The ignorant man,” he warned, “may underdose himself and by exposing his microbes to non-lethal quantities of the drug, make them resistant.